EMA CHMP gives positive opinion on daratumumab use in smouldering myeloma patients with high risk of developing myeloma
On the 19th June 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorisation for daratumumab for patients with high-risk smouldering myeloma. Daratumumab is a monoclonal antibody marketed by Johnson & Johnson as…